| Database . | Rate of GNB, % . | Resistance to CRO, % . | Resistance to FEP, % . | Resistance to MEM, % . |
|---|---|---|---|---|
| OneHealth | 55.04 | 24.09 | … | 2.14 |
| Sentry | 55.52 | 45.40 | 4.41 | 5.26 |
| NHSN | 62.77 | 45.42 | 9.47 | 1.45 |
| Median (IQR) | 55.52 (55.25–59.15) | 45.40 (34.75–45.41) | 6.94 (5.68–8.20) | 2.14 (1.79–3.70) |
| Database . | Rate of GNB, % . | Resistance to CRO, % . | Resistance to FEP, % . | Resistance to MEM, % . |
|---|---|---|---|---|
| OneHealth | 55.04 | 24.09 | … | 2.14 |
| Sentry | 55.52 | 45.40 | 4.41 | 5.26 |
| NHSN | 62.77 | 45.42 | 9.47 | 1.45 |
| Median (IQR) | 55.52 (55.25–59.15) | 45.40 (34.75–45.41) | 6.94 (5.68–8.20) | 2.14 (1.79–3.70) |
Abbreviations: CRO, ceftriaxone; FEP, cefepime; GNB, gram-negative bacilli; IQR, interquartile range; MEM, meropenem; NHSN, National Healthcare Safety Network.
| Database . | Rate of GNB, % . | Resistance to CRO, % . | Resistance to FEP, % . | Resistance to MEM, % . |
|---|---|---|---|---|
| OneHealth | 55.04 | 24.09 | … | 2.14 |
| Sentry | 55.52 | 45.40 | 4.41 | 5.26 |
| NHSN | 62.77 | 45.42 | 9.47 | 1.45 |
| Median (IQR) | 55.52 (55.25–59.15) | 45.40 (34.75–45.41) | 6.94 (5.68–8.20) | 2.14 (1.79–3.70) |
| Database . | Rate of GNB, % . | Resistance to CRO, % . | Resistance to FEP, % . | Resistance to MEM, % . |
|---|---|---|---|---|
| OneHealth | 55.04 | 24.09 | … | 2.14 |
| Sentry | 55.52 | 45.40 | 4.41 | 5.26 |
| NHSN | 62.77 | 45.42 | 9.47 | 1.45 |
| Median (IQR) | 55.52 (55.25–59.15) | 45.40 (34.75–45.41) | 6.94 (5.68–8.20) | 2.14 (1.79–3.70) |
Abbreviations: CRO, ceftriaxone; FEP, cefepime; GNB, gram-negative bacilli; IQR, interquartile range; MEM, meropenem; NHSN, National Healthcare Safety Network.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
